Cetera Investment Advisers Sells 91,555 Shares of Pfizer Inc. (NYSE:PFE)

Cetera Investment Advisers lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,110,531 shares of the biopharmaceutical company’s stock after selling 91,555 shares during the period. Cetera Investment Advisers’ holdings in Pfizer were worth $59,053,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Pfizer during the second quarter valued at approximately $31,000. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. StockNews.com lowered Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, September 16th. UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Down 0.9 %

Shares of NYSE:PFE opened at $28.67 on Wednesday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.11. The company has a market cap of $162.46 billion, a PE ratio of -477.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. The stock has a 50 day moving average of $29.28 and a 200 day moving average of $28.31. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm earned $0.67 EPS. The company’s revenue was up 2.1% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.